INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

Core Viewpoint - The Ultragenyx class action lawsuit alleges that the company and its executives made misleading statements regarding the efficacy of setrusumab in treating Osteogenesis Imperfecta, leading to significant stock price declines when the truth was revealed [4][5][6]. Company Overview - Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing treatments for rare and ultra-rare genetic diseases [3]. Allegations of the Lawsuit - The lawsuit claims that Ultragenyx misrepresented the reliability of information regarding setrusumab's effects and downplayed the risks associated with the Phase III Orbit study, which ultimately failed to show statistically significant results [4]. - On July 9, 2025, Ultragenyx disclosed that the Phase III Orbit study did not achieve statistical significance, resulting in a stock price drop of over 25% [5]. - On December 29, 2025, the company announced that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, causing a further stock price decline of more than 42% [6]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Ultragenyx stock during the class period to seek appointment as lead plaintiff in the lawsuit, representing the interests of all class members [7]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities class action recoveries, having recovered over $916 million for investors in 2025 alone, and a total of $8.4 billion over the past five years [8].